Cytokinetics, Incorporated (CYTK)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
72.09 USD
-5.81
(-7.458%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 72.50 +0.41 (0.569%) ⇧ (Aug. 28, 2026, 7:38 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:54 a.m. EDT
Cytokinetics is a high-risk turnaround play where the stock price has recovered 215% over the last nine years, yet the company is currently burning cash with revenue contracting by nearly 57%. While analysts maintain a strong buy stance with a target price implying significant upside, the fundamentals are fragile with negative earnings and free cash flow. The short-term outlook is neutral to slightly cautious; the stock has slipped below its 50-day moving average and insiders have been selling shares, even though the 200-day average provides a floor. There is no dividend income to offset the capital risk. Investors should view this as a speculative bet on the company's pipeline rather than a value investment, as the financial health remains precarious despite the strong analyst consensus. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.039924 |
| AutoETS | 0.039925 |
| MSTL | 0.041468 |
| AutoTheta | 0.070102 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 1.76 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.610 |
| Excess Kurtosis | -0.71 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.544 |
| Market Cap | 10,022,198,272 |
| Forward P/E | -16.20 |
| Beta | 0.38 |
| Website | https://www.cytokinetics.com |
As of Aug. 22, 2026, 2:54 a.m. EDT: Speculators are positioning for elevated volatility with implied volatility significantly above the market average. Near-term expirations show heavy open interest on out-of-the-money calls at the 85 and 90 strikes, suggesting a bullish bias for a breakout, while substantial put open interest at the 60 strike indicates downside hedging. Long-dated contracts reveal unusual volume and IV spikes at deep in-the-money strikes, implying asymmetric bets on either a massive rally or a prolonged drawdown.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5699315 |
| Address1 | 350 Oyster Point Boulevard |
| All Time High | 110.25 |
| All Time Low | 3.05 |
| Ask | 91.94 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 1,440,040 |
| Average Daily Volume3 Month | 2,006,379 |
| Average Volume | 2,006,379 |
| Average Volume10Days | 1,440,040 |
| Beta | 0.376 |
| Bid | 72.3 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | -1.25 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 72.09 |
| Current Ratio | 6.661 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 74.4 |
| Day Low | 71.69 |
| Earnings Call Timestamp End | 1,786,046,400 |
| Earnings Call Timestamp Start | 1,786,046,400 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -695,361,984 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -14.785 |
| Enterprise To Revenue | 151.928 |
| Enterprise Value | 10,280,967,168 |
| Eps Current Year | -5.94458 |
| Eps Forward | -4.45068 |
| Eps Trailing Twelve Months | -6.68 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 80.088 |
| Fifty Day Average Change | -7.998001 |
| Fifty Day Average Change Percent | -0.09986517 |
| Fifty Two Week Change Percent | 56.99315 |
| Fifty Two Week High | 88.31 |
| Fifty Two Week High Change | -16.220001 |
| Fifty Two Week High Change Percent | -0.18367118 |
| Fifty Two Week Low | 44.91 |
| Fifty Two Week Low Change | 27.179996 |
| Fifty Two Week Low Change Percent | 0.60521036 |
| Fifty Two Week Range | 44.91 - 88.31 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,083,331,800,000 |
| Float Shares | 138,386,691 |
| Forward Eps | -4.45068 |
| Forward P E | -16.197525 |
| Free Cashflow | -397,408,736 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 673 |
| Fullday Change | -5.81001 |
| Fullday Change Percent | -7.45829 |
| Fullday Price | 72.5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -337,436,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0064999997 |
| Held Percent Institutions | 1.25753 |
| Implied Shares Outstanding | 139,023,418 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://phx.corporate-ir.net/phoenix.zhtml?c=142156&p=irol-IRHome |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,372,118,400 |
| Last Split Factor | 1:6 |
| Long Business Summary | Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California. |
| Long Name | Cytokinetics, Incorporated |
| Market | us_market |
| Market Cap | 10,022,198,272 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_27315 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -894,001,984 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 10,843,826,604 |
| Number Of Analyst Opinions | 20 |
| Open | 73.552 |
| Operating Cashflow | -555,452,992 |
| Operating Margins | -6.2595 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 650 624 3000 |
| Post Market Change | 0.41000366 |
| Post Market Change Percent | 0.56873864 |
| Post Market Price | 72.5 |
| Post Market Time | 1,787,960,310 |
| Previous Close | 77.9 |
| Price Eps Current Year | -12.127012 |
| Price Hint | 2 |
| Price To Book | -57.671997 |
| Price To Sales Trailing12 Months | 148.104 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.56 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -5.81001 |
| Regular Market Change Percent | -7.45829 |
| Regular Market Day High | 74.4 |
| Regular Market Day Low | 71.69 |
| Regular Market Day Range | 71.69 - 74.4 |
| Regular Market Open | 73.552 |
| Regular Market Previous Close | 77.9 |
| Regular Market Price | 72.09 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 4,360,330 |
| Return On Assets | -0.2809 |
| Revenue Growth | -0.571 |
| Revenue Per Share | 0.544 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 139,023,418 |
| Shares Percent Shares Out | 0.1174 |
| Shares Short | 16,323,712 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 17,051,981 |
| Short Name | Cytokinetics, Incorporated |
| Short Percent Of Float | 0.1792 |
| Short Ratio | 8.95 |
| Source Interval | 15 |
| State | CA |
| Symbol | CYTK |
| Target High Price | 146.0 |
| Target Low Price | 85.0 |
| Target Mean Price | 109.9 |
| Target Median Price | 107.5 |
| Total Cash | 1,165,686,016 |
| Total Cash Per Share | 8.385 |
| Total Debt | 1,424,455,040 |
| Total Revenue | 67,670,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -6.68 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 69.56565 |
| Two Hundred Day Average Change | 2.5243454 |
| Two Hundred Day Average Change Percent | 0.03628724 |
| Type Disp | Equity |
| Volume | 4,360,330 |
| Website | https://www.cytokinetics.com |
| Zip | 94,080 |